No CrossRef data available.
Article contents
Lamictal
Published online by Cambridge University Press: 18 September 2015
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
- Type
- Index
- Information
- Copyright
- Copyright © Canadian Neurological Sciences Federation 1977
References
References:
1.
Goa, KL
el al. Lamotrigine: A review of its pharmacological properties and dinical efficacy in epilepsy. Drugs
1993;46(1):152–176.Google Scholar
2.
Leach, MJ
et al. Neurochemical and behavkxal aspects of lamotrigine. Epilepsia
1991;32(Suppl.2):S4–S8.CrossRefGoogle ScholarPubMed
3. Data on file Glaxo Wellcome (GWMN[2]:09/96).Google Scholar
4.
Brodie, MJ
Lamotrigine versus other antiepileptic drugs: A star rating system is born. Epilepsia
1994;35(Suppl.5):S41–46.Google Scholar
6.
Richens, A, Yuen, AWC. Overview of the clinical efficacy of lamotrigine. Epilepsia
1991;32(Suppl.2):S13–S16.Google Scholar
8.
Binnie, CD
et al. Acute effects of lamotrigine (BW 430C) in persons with epilepsy. Epilepsia
1986;27(3)248–254.Google Scholar
9.
Sander, JWAS
et al
A randomised double-blind placebo-controlled add-on trial of lamtrigine in patients with severe epilepsy. Epilepsy Res
1990;6(3):221–226.Google Scholar
10.
Yuen, AWC
Lamotrigine: A review of antiepileptic efficacy. Epilepsia
1994;35(Suppl.5):S33–S3.CrossRefGoogle ScholarPubMed
11.
Binne, CD
Lamotrigine. Comprehensive Epleptology. New York Raven Press
1990:665–670.Google Scholar
12.
Binne, CD
et al. Double-blind crossover tiral of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res
1989;4(3)222–229.Google Scholar
13.
Dren, AT
et al
Placebo-controlled, dose-response evaluation of the efficacy and safety of motrigine (LAMICTA) as add-on therapy in epileptic outpatients with partial seizures. Epilepsia
1991:32 (Suppl.3)2.Google Scholar
14.
Gay, PE
et al. Chronic dose tolerance of lamotrigine and placebo in patients with epilepsy. Epilepsia
1988;29(5):686.Google Scholar
15.
Jawad, S
et al. Controlled trial of lamotrigiie (Lamictal) for refractory partial seizures. Epilepsia
1989;30(3):356–363.CrossRefGoogle ScholarPubMed
16.
Loiseau, P
et al. A randomised double-bilnd placebo-controlled crossover add-on trial of lamotrigine it patient with trealment-resistant partial seizures. Epilepsy fles
1990;7(2):136–145.Google Scholar
17.
Matsuo, F
et al. Placebo-controled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology
1993;43:2284–2291.Google Scholar
18.
Messenheimer, J
et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia
1994;35(1):113–121.Google Scholar
19.
Mikati, MA
et al. Long-term tolerability, pharmacokinetic and preliminary efficacy study of Lamotrigine in patients with resistant partial seizures. Neuropharmacol
1989;12(4):312–321.Google Scholar
21.
Risner, ME
et al. Multicenter, double-blind, placebo-controlled, add-on, crossover study of lamotrigine (Lamictal) in epileptic outpatients with partial seizures. Epilepsia
1990;31(5):619–620.Google Scholar
22.
Schapel, GJ
et al. No effect of lamotrigine on carbamazepine and mazepine-epoxide concentrations. Epilepsia
1991;32 (Suppl.1):58.Google Scholar
23.
Smith, D
et al. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia
1993;34(2);312–322.Google Scholar
26.
Cohen, AF
et al. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol
1985;20:619–629.Google Scholar
You have
Access